Inflammatory diseases don’t boost clotting risks post-COVID, study reveals

Canadian researchers found that patients with immune-mediated inflammatory diseases (IMIDs) don’t face a heightened risk of venous thromboembolism events after recovering from COVID-19 compared to those without IMIDs. However, certain comorbidities can influence this risk, emphasizing the importance of individualized patient care.

Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management

Tirzepatide, a novel twincretin drug, significantly improves weight loss and glycemic control in obese and type 2 diabetes patients, outperforming traditional treatments in clinical trials.

July 15, 2024

Federal officials will fund farms’ protective measures to contain H5N1 bird flu

WASHINGTON — The federal government will provide livestock farms as much as $28,000 apiece to bolster protective measures and testing for the avian flu virus

May 10, 2024

Exploring the role of chemokines in atrial fibrillation development

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Chemokines are a subclass of cytokines, a large family of small secreted proteins that

September 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.